Eisai
Sports
Submits
Eisai Submits Marketing Authorization Application in Japan for Anticancer Agent...
Eisai Submits Marketing Authorization Application in Japan for Anticancer Agent Tasurgratinib for Biliary Tract Cancer with Fgfr2 Gene Fusion TOKYO,...